<DOC>
	<DOCNO>NCT02029326</DOCNO>
	<brief_summary>Prometheus 's Onco dX assay platform provide technological breakthrough immunoassay obtain level sensitivity single tumor cell without compromise specificity . This allow assessment multiple TKI treatment target , activation status , well stream signal protein use tiny amount tissue obtain FNA CTCs . We plan study explore biomarkers predictive clinical response cetuximab-based treatment metastatic colorectal cancer use Prometheus Platform . We also elucidate signal transduction pathway attributable cetuximab resistance , monitor change RTK activation status cetuximab treatment use circulate tumor cell analyze correlation quantity circulate tumor cell treatment response cetuximab .</brief_summary>
	<brief_title>Biomarker Analysis Metastatic Colorectal Cancer Treated With Cetuximab</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Patients histologically confirm metastatic colorectal cancer Cetuximabbased chemotherapy ( monotherapy , combination therapy cytotoxic chemotherapy FOLFOX , XELOX , irinotecan , FOLFIRI , XELIRI , firstline , secondline thirdline eligible ) Age &gt; 18 year . ECOG Performance Status 02 Adequate bone marrow , liver renal function Signed date informed consent start specific protocol procedure . FNA perform patient feasible biopsy site ; ascites pleural fluid collect metastatic CRC patient ascites pleural effusion Active clinically serious infection ( &gt; grade 2 CTCAE version 3.0 ) Patients evidence history bleed diathesis Radiotherapy study within 4 week start study drug . Prior exposure study drug . Substance abuse , medical , psychological social condition may interfere patient 's participation study evaluation study result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>colorectal cancer , cetuximab , biomarker , prometheus</keyword>
</DOC>